1. Sumnall HR, Cole JC, Jerome L (2006) The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy. J Psychopharmacol 20(5):670–682

2. de la Torre R, Farre M, Roset PN, Lopez CH, Mas M, Ortuno J, Menoyo E, Pizarro N, Segura J, Cami J (2000) Pharmacology of MDMA in humans. Ann NY Acad Sci 914:225–237

3. Downing J (1986) The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 18:335–340

4. Cami J, Farre M, Mas M, Roset RN, Poudevida S, Mas A, San L, de la Torre R (2000) Human pharmacology of 3,4-methylenedioxymethamphetamine (“Ecstasy”): psychomotor performance and subjective effects. J Clin Psychopharm 20(4):455–466

5. Lacey JH, Kelley-Baker T, Furr-Holden D, Voas RB, Romano E, Ramirez A, Brainard K, Moore C, Torres P, Berning A (2009) 2007 National Roadside Survey of Alcohol and Drug Use by Drivers: Drug Results. National Highway Traffic Safety Administration Office of Behavioral Safety Research. http://www.nhtsa.gov/Driving+Safety/Research+&+Evaluation/2007+National+Roadside+Survey+of+Alcohol+and+Drug+Use+by+Drivers. Accessed 15 Aug 2013

6. Substance Abuse and Mental Health Services Administration (2010) Results from the 2009 National Survey on Drug Use and Health: National Findings NSDUH Series H-38A. Department of Health and Human Services (DHHS), Rockville, MD. http://www.samhsa.gov/data/2k9/2k9Resultsweb/web/2k9results.htm. Accessed 15 Aug 2013

7. Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA (2008) Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit 30(3):320–332

8. Meyer MR, Peters FT, Maurer HH (2008) The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its enantiomers. Drug Metab Dispos 36(11):2345–2354

9. Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA (2008) Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol 28(4):432–440

10. Farre M, de la Torre R, Mathuna BO, Roset PN, Peiro AM, Torrens M, Ortuno J, Pujadas M, Cami J (2004) Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl) 173(3–4):364–375

11. Peiro AM, Farre M, Roset PN, Carbo M, Pujadas M, Torrens M, Cami J, de la Torre R (2013) Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart. Psychopharmacology (Berl) 225(4):883–893

12. Ramaekers JG, Kuypers KP, Samyn N (2006) Stimulant effects of 3,4-methylenedioxymethamphetamine (MDMA) 75 mg and methylphenidate 20 mg on actual driving during intoxication and withdrawal. Addiction 101(11):1614–1621

13. Pizarro N, Farre M, Pujadas M, Peiro AM, Roset PN, Joglar J, de la Torre R (2004) Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). Drug Metab Dispos 32(9):1001–1007

14. Mueller M, Peters FT, Huestis MA, Ricaurte GA, Maurer HH (2009) Simultaneous liquid chromatographic-electrospray ionization mass spectrometric quantification of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and its metabolites 3,4-dihydroxymethamphetamine, 4-hydroxy-3-methoxymethamphetamine and 3,4-methylenedioxyamphetamine in squirrel monkey and human plasma after acidic conjugate cleavage. Forensic Sci Int 184(1–3):64–68

15. Peters FT, Samyn N, Lamers CT, Riedel WJ, Kraemer T, de Boeck G, Maurer HH (2005) Drug testing in blood: validated negative-ion chemical ionization gas chromatographic-mass spectrometric assay for enantioselective measurement of the designer drugs MDEA, MDMA, and MDA and its application to samples from a controlled study with MDMA. Clin Chem 51(10):1811–1822

16. Desrosiers NA, Barnes AJ, Hartman RL, Scheidweiler KB, Kolbrich-Spargo EA, Gorelick DA, Goodwin RS, Huestis MA (2013) Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration. Anal Bioanal Chem 405(12):4067–4076

17. Kolbrich EA, Lowe RH, Huestis MA (2008) Two-dimensional gas chromatography/electron-impact mass spectrometry with cryofocusing for simultaneous quantification of MDMA, MDA, HMMA, HMA, and MDEA in human plasma. Clin Chem 54:379–387

18. Scientific Working Group for Forensic Toxicology (SWGTOX) (2013) Standard practices for method validation in forensic toxicology. http://www.swgtox.org/documents/Validation3.pdf Acessed 15 Aug 2013

19. Scheidweiler KB, Barnes AJ, Huestis MA (2008) A validated gas chromatographic-electron impact ionization mass spectrometric method for methamphetamine, methylenedioxymethamphetamine (MDMA), and metabolites in mouse plasma and brain. J Chromatogr B 876(2):266–276

20. Helmlin H, Bracher K, Bourquin D, Vonlanthen D, Brenneisen R (1996) Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS. J Anal Toxicol 20:432–440

21. Clauwaert KM, Van Bocxlaer JF, DeLetter EA, Van Calenbergh S, Lambert WE, De Leenheer AP (2000) Determination of the designer drugs 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxyethylamphatamine, and 3,4-methylenedioxyamphetamine with HPLC and fluorescence detection in whole blood, serum, vitreous humor, and urine. Clin Chem 46:1968–1977

22. Cheze M, Deveaux M, Martin C, Lhermitte M, Pepin G (2007) Simultaneous analysis of six amphetamines and analogues in hair, blood and urine by LC-ESI-MS/MS. Application to the determination of MDMA after low ecstasy intake. Forensic Sci Int 170(2–3):100–104

23. Middleberg RA, Homan J (2012) Quantitation of amphetamine-type stimulants by LC-MS/MS. Methods Mol Biol 902:105–114

24. Bjork MK, Nielsen MK, Markussen LO, Klinke HB, Linnet K (2010) Determination of 19 drugs of abuse and metabolites in whole blood by high-performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 396(7):2393–2401

25. da Silva DG, de Pinho PG, Pontes H, Ferreira L, Branco P, Remiao F, Carvalho F, Bastos ML, Carmo H (2010) Gas chromatography-ion trap mass spectrometry method for the simultaneous measurement of MDMA (ecstasy) and its metabolites, MDA, HMA, and HMMA in plasma and urine. J Chromatogr B 878(9–10):815–822

26. Tomita M, Nakashima MN, Wada M, Nakashima K (2007) Sensitive determination of MDMA and its metabolite MDA in rat blood and brain microdialysates by HPLC with fluorescence detection. Biomed Chromatogr 21(10):1016–1022

27. Jantos R, Veldstra JL, Mattern R, Brookhuis KA, Skopp G (2011) Analysis of 3,4-methylenedioxymetamphetamine: whole blood versus dried blood spots. J Anal Toxicol 35(5):269–273

28. Navarro M, Pichini S, Farre M, Ortuno J, Roset PN, Segura J, de La Torre R (2001) Usefulness of saliva for measurement of 3,4-methylenedioxymehamphetamine and its metabolites: correlation with plasma drug concentrations and effect of salivary pH. Clin Chem 47:1788–1795

29. Moffat AC, Osselton MD, Widdop B, Galichet LY (2004) Clarke’s analysis of drugs and poisons in pharmaceuticals, body fluids and postmortem material, 3rd edn. Pharmaceutical Press, London

30. Clauwaert KM, Van Bocxlaer JF, De Leenheer AP (2001) Stability study of the designer drugs “MDA, MDMA and MDEA” in water, serum, whole blood, and urine under various storage temperatures. Forensic Sci Int 124:36–42

31. Garrett ER, Seyda K, Marroum P (1991) High performance liquid chromatographic assays of the illicit designer drug “Ecstasy”, a modified amphetamine, with applications to stability, partitioning and plasma protein binding. Acta Pharm Nord 3(1):9–14

32. Belhadj-Tahar H, Payoux P, Tafani M, Coulais Y, Calet S, Bousseksou A (2010) Toxicological methods for tracing drug abuse: chromatographic, spectroscopic and biological characterisation of ecstasy derivatives. Arh Hig Rada Toksikol 61(1):53–59

33. Capela JP, Carmo H, Remiao F, Bastos ML, Meisel A, Carvalho F (2009) Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol 39(3):210–271

34. Yubero-Lahoz S, Pardo R, Farre M, Mathuna BO, Torrens M, Mustata C, Perez-Mana C, Langohr K, Carbo ML, de la Torre R (2012) Changes in CYP1A2 activity in humans after 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) administration using caffeine as a probe drug. Drug Metab Pharmacokinet 27(6):605–613

35. Yubero-Lahoz S, Pardo R, Farre M, O’Mahony B, Torrens M, Mustata C, Perez-Mana C, Carbo ML, de la Torre R (2011) Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. Clin Pharmacokinet 50(5):319–329